Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
IVIG Therapy for Cancer Patients: Benefits, Risks, and What the Research Shows
IVIG Therapy for Cancer Patients: Benefits, Risks, and What the Research Shows
Cancer and cancer treatments can weaken the immune system. For some patients, this immune suppression becomes severe enough that recurrent infections become a major threat to survival and quality of life.
One treatment oncologists may recommend is intravenous immunoglobulin (IVIG) therapy. IVIG is not a chemotherapy drug, immunotherapy, or targeted therapy. Instead, it is a supportive-care treatment made from antibodies collected from healthy donors and administered through an intravenous infusion.
While IVIG can reduce infection risk in selected patients, it is expensive, time-consuming, and carries potential side effects ranging from headaches to blood clots.
Before beginning IVIG therapy, it is important to understand both the potential benefits and risks.
What Is IVIG?
IVIG stands for intravenous immunoglobulin.
The treatment contains concentrated antibodies (immunoglobulins) obtained from thousands of healthy blood donors. These antibodies help strengthen the immune defenses of patients who cannot produce adequate antibodies on their own.
IVIG is commonly used in cancer patients who develop:
- Hypogammaglobulinemia (low antibody levels)
- Recurrent bacterial infections
- Secondary immune deficiency caused by chemotherapy
- Chronic lymphocytic leukemia (CLL)
- Multiple myeloma
- Non-Hodgkin lymphoma
- CAR-T cell therapy–related immune deficiency
Why Cancer Patients Develop Antibody Deficiency
Many blood cancers directly damage antibody-producing B cells.
Examples include:
- Chronic lymphocytic leukemia (CLL)
- Multiple myeloma
- Certain lymphomas
In addition, cancer treatments such as:
- Anti-CD20 antibodies (rituximab and similar drugs)
- CAR-T therapy
- Stem cell transplantation
- Intensive chemotherapy
can significantly reduce antibody production and increase infection risk.
For these patients, recurrent pneumonia, sinus infections, urinary tract infections, and bloodstream infections can become a serious problem.
Potential Benefits of IVIG Therapy
1. Reduced Risk of Serious Infections
The strongest evidence supporting IVIG involves prevention of recurrent infections in patients with antibody deficiencies.
Studies in patients with CLL, lymphoma, and multiple myeloma have demonstrated reductions in bacterial infections following IVIG treatment. Several guidelines recommend considering IVIG when patients have both significant hypogammaglobulinemia and recurrent serious infections.
More recent studies continue to show meaningful reductions in infection rates among appropriately selected patients.
2. Fewer Hospitalizations
Serious infections frequently result in emergency department visits and hospital admissions.
By preventing recurrent infections, IVIG may help reduce hospitalization rates and allow patients to remain on their planned cancer treatments.
3. Improved Quality of Life
Repeated infections can cause:
- Fatigue
- Missed work
- Treatment delays
- Reduced physical activity
- Increased anxiety
Many patients who experience fewer infections report improved quality of life and fewer interruptions to daily living.
4. May Help Patients Receiving CAR-T Therapy
CAR-T cell therapies often cause prolonged B-cell depletion and severe hypogammaglobulinemia.
For patients who develop recurrent infections after CAR-T treatment, IVIG may be considered as part of long-term supportive care.
Risks and Side Effects of IVIG
Although generally considered safe, IVIG is not risk-free.
Common Side Effects
Most adverse effects are mild and temporary.
Common side effects include:
- Headache
- Chills
- Fever
- Fatigue
- Muscle aches
- Nausea
- Flushing
- Mild allergic reactions
These symptoms often improve by slowing the infusion rate or increasing hydration.
Blood Clots (Thromboembolism)
One of the most concerning complications is thrombosis.
IVIG has been associated with:
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Stroke
- Heart attack
Risk appears highest in patients who already have cardiovascular disease, clotting disorders, advanced age, or other thrombotic risk factors.
Kidney Injury
Rarely, IVIG can impair kidney function.
Patients with:
- Existing kidney disease
- Diabetes
- Dehydration
- Older age
may require careful monitoring before and during treatment.
Allergic Reactions
Severe allergic reactions are uncommon but can occur.
Symptoms may include:
- Wheezing
- Low blood pressure
- Facial swelling
- Anaphylaxis
Patients are monitored closely during infusions for this reason.
Aseptic Meningitis
Rarely, patients develop severe headaches, neck stiffness, and meningitis-like symptoms after IVIG treatment.
Most cases resolve once therapy is stopped.
Who Is Most Likely to Benefit?
Current evidence suggests IVIG is most appropriate for patients who have:
- Documented hypogammaglobulinemia
- Recurrent severe infections
- Poor response to antibiotics
- CLL
- Certain lymphomas
- Multiple myeloma
- Post-CAR-T immune deficiency
Many guidelines recommend reserving IVIG for patients with both low IgG levels and a history of significant infections rather than using it routinely in all cancer patients.
Who May Not Need IVIG?
Most solid tumor patients do not require IVIG.
Likewise, patients who have:
- Normal antibody levels
- No history of recurrent infections
- Mild immune suppression
may gain little benefit from routine IVIG treatment.
Because IVIG is expensive and donor-derived, most experts recommend individualized use rather than universal treatment.
Questions to Ask Your Oncologist
Before starting IVIG, consider asking:
- What are my current IgG levels?
- Have my infections become severe enough to justify IVIG?
- What are my blood clot risks?
- How often would I receive infusions?
- How long would treatment continue?
- Could subcutaneous immunoglobulin (SCIG) be an alternative?
- Are there other infection-prevention strategies I should use?
The Bottom Line
IVIG can be a valuable supportive-care therapy for selected cancer patients with severe antibody deficiency and recurrent infections. Research suggests it can reduce bacterial infections, decrease hospitalization risk, and improve quality of life in appropriately chosen patients.
However, IVIG is not a cure for cancer and should not be viewed as a treatment for the underlying malignancy. Potential risks—including blood clots, kidney injury, allergic reactions, and infusion-related side effects—must be balanced against the potential benefits.
For patients with CLL, multiple myeloma, lymphoma, or CAR-T therapy–related immune deficiency, a discussion with an oncologist about IVIG may be worthwhile if recurrent infections are becoming a problem.
Research References
- Cleveland Clinic. IVIG Overview:
https://my.clevelandclinic.org/health/treatments/ivig-intravenous-immunoglobulin - Noto A, et al. Treatment of hypogammaglobulinemia in CLL:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10140292/ - Khan S, et al. Immunoglobulin replacement in CLL:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10117948/ - Soumerai JD, et al. IgG testing and immunoglobulin replacement:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11372570/ - Milani C, et al. Thromboembolic complications of IVIG:
https://pmc.ncbi.nlm.nih.gov/articles/PMC2803875/ - Ammann EM, et al. IVIG and thromboembolic events:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4713161/ - Oncology Nursing Society. IVIG for prevention of infection:
https://www.ons.org/clinical-tools/symptom-management-resources/prevention-infection-general/intravenous-immunoglobulin - Link H, et al. Guideline adherence for immunoglobulin replacement in CLL and MM:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9046374/
To learn more:
Link TO this article from:
- Multiple Myeloma and Infection Risk
- Multiple Myeloma Immune Recovery
- CAR-T Cell Therapy Side Effects
- Chemotherapy and Low Blood Counts
- Managing Cancer-Related Fatigue
- Cancer Survivor Infection Prevention
- Stem Cell Transplant Recovery
- Multiple Myeloma Supportive Care
Link FROM this article TO:
- Multiple Myeloma Symptoms
- Chemotherapy-Induced Immunosuppression
- Medicinal Mushrooms and Cancer
- Vitamin D3 and Cancer
- Anti-Cancer Foods
- Exercise During Chemotherapy
- Immune Recovery After Chemotherapy
- Integrative Oncology: What the Science Shows